Core Insights - TScan Therapeutics, Inc. has announced the acceptance of two abstracts for presentation at the ACR Convergence 2025, focusing on novel targets in T cell-driven autoimmune disorders [1][2] - The company aims to leverage its proprietary TargetScan technology to identify therapeutic targets for conditions like Ankylosing Spondylitis, which have been challenging to address in past research [2] Presentation Details - The oral presentation titled "TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis" is scheduled for October 27, 2025, from 10:00 to 11:30 a.m. Central Time, with the specific presentation time set for 10:45 to 11:00 a.m. [3] - A poster presentation titled "Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan" will also take place on October 27, 2025, from 10:30 a.m. to 12:30 p.m. Central Time [4] Company Overview - TScan Therapeutics is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, with ongoing clinical trials for hematologic malignancies and solid tumors [5]